Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMV Vaccine Therapy Alone and TMV Vaccine Plus Pembrolizumab for Recurrent and/or Metastatic HNSCC
NCT06868433Phase 1Recruiting
- Sponsor
- Emory University
- Start
- May 2025
- Primary completion
- Jan 2028
- Modality
- Lipid-based Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous tumor membrane vesicles vaccine in head and neck squamous cell carcinoma (HNSCC) (2 cohorts), sponsored by Emory University. Primary endpoints: Dose-limiting toxicity at 7 weeks, Treatment-emergent adverse events and 1 more. Started May 2025; status: recruiting.
02
Drugs
autologous tumor membrane vesicles vaccine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06868433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06868433.